文献速递基础与转化研究临床试验与 GCP

Anito-cel(d结构域BCMA CAR T细胞)治疗复发或难治性骨髓瘤的1期研究

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
PubMed 文献 · N Engl J Med · 2026-01-01

这项1期研究评估了靶向BCMA的CAR T细胞疗法anito-cel在复发或难治性多发性骨髓瘤患者中的安全性和疗效。38例接受治疗的患者中,推荐2期剂量组细胞因子释放综合征均为1-2级,无3级及以上事件;中位随访38.1个月时全部患者有响应,79%达完全缓解。

要点

  • 推荐2期剂量(100×10^6 CAR+ T细胞)下细胞因子释放综合征均为1-2级,无3级及以上事件。
  • 38例可评估患者全部有响应,79%达完全缓解。
  • 24个月无进展生存率为57%,中位无进展生存期30.2个月,36个月总生存率65%。

核心结论

  • Anito-cel在重度经治的复发或难治性多发性骨髓瘤患者中引起高响应率,3级及以上细胞因子释放综合征和ICANS罕见。

研究设计与样本

  • 1期研究评估anito-cel两个剂量水平(1级100×10^6 CAR+ T细胞,2级300×10^6 CAR+ T细胞)。
  • 入组患者为既往接受≥3线治疗或三重难治的复发或难治性多发性骨髓瘤患者。
  • 主要终点为治疗期间不良事件和推荐2期剂量的确定。
  • 纳入40例患者,38例接受anito-cel治疗。

主要发现

  • 全部38例患者在治疗期间发生不良事件,37例(97%)发生3级及以上不良事件。
  • 推荐2期剂量组中94%发生1-2级细胞因子释放综合征,无3级及以上事件。
  • 16%的患者发生1-2级ICANS,1例(3%)发生3级事件;无其他神经毒性事件。
  • 中位随访38.1个月时,全部38例(100%)有响应,79%达完全缓解。
  • 24个月无进展生存率57%,中位无进展生存期30.2个月,36个月总生存率65%。

关键数值与推荐

  • 推荐2期剂量为100×10^6 CAR+ T细胞。
  • ddBCMA结合子的解离速率快于双VHH结合子;两者细胞毒性相似,但ddBCMA CAR T细胞细胞因子释放更少,且无抗原非依赖性激活或脱靶细胞毒效应。

临床怎么用

  • anito-cel在重度经治复发或难治性多发性骨髓瘤中显示高响应率和可控的细胞因子释放综合征与神经毒性。
  • 推荐2期剂量下未见3级及以上细胞因子释放综合征,3级及以上ICANS罕见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor (CAR) T-cell therapy with a synthetic d-domain binder (ddBCMA), may have efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In a phase 1 study, we evaluated the safety and efficacy of anito-cel (dose level 1, 100×106 CAR+ T cells; dose level 2, 300×106 CAR+ T cells) in patients with relapsed or refractory multiple myeloma who had received three or more lines of therapy previously or had triple-class refractory disease. Primary end points were adverse events during the treatment period and establishment of the recommended phase 2 dose. In complementary in vitro studies, we compared the anito-cel ddBCMA binder with a dual variable heavy-chain domain of a heavy chain-only antibody (dual-VHH) binder corresponding to the published sequence for ciltacabtagene autoleucel. RESULTS: Of 40 patients enrolled, 38 received anito-cel. All 38 patients had an adverse event during the treatment period, and 37 patients (97%) had an adverse event of grade 3 or higher. Among patients who received the recommended phase 2 dose (100×106 CAR+ T cells), 94% had cytokine release syndrome of grade 1 or 2, with no events of grade 3 or higher. A total of 16% of the patients had immune effector cell-associated neurotoxicity syndrome (ICANS) of grade 1 or 2, and 1 patient (3%) had a grade 3 event. No non-ICANS or delayed neurotoxic effects occurred. At a median follow-up of 38.1 months, all 38 patients (100%) had had a response, with 79% having a complete response. The 24-month progression-free survival was 57%; the median progression-free survival was 30.2 months. The 36-month overall survival was 65%. The ddBCMA binder had a faster off-rate than the dual-VHH binder; although cytotoxicity was similar with the two therapies, ddBCMA CAR T cells led to less cytokine release and did not result in activation without antigen or in off-target cytotoxic effects. CONCLUSIONS: Anito-cel therapy led to a high incidence of response among patients with heavily pretreated relapsed or refractory multiple myeloma. Cytokine release syndrome and ICANS of grade 3 or higher were rare. (Funded by Arcellx and Kite, a Gilead company; ClinicalTrials.gov number, NCT04155749.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Frigault MJ, Dhakal B, Jakubowiak AJ, et al. Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026. PMID: 42777241. doi:10.1056/NEJMoa2603527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。